Vorozole
A third-generation non-steroidal triazole aromatase inhibitor (Rivizor) studied for breast cancer but never widely marketed. It is highly selective and potent, structurally related to anastrozole and letrozole.
01 Overview
Vorozole (Rivizor) is a triazole non-steroidal aromatase inhibitor from the same generation as anastrozole and letrozole. It was studied in advanced and neoadjuvant breast cancer, showing potent, selective estradiol suppression, but development was discontinued and it never gained broad approval.
Human data are more limited than for the marketed triazoles, hence a lower research score, but its mechanism and side-effect profile mirror the AI class.
02 Mechanism
Non-steroidal (type II) selective aromatase inhibitor: reversibly binds aromatase heme iron, blocking androgen-to-oestrogen conversion.
03 Dosing
| Tier | Dose | Route | Notes |
|---|---|---|---|
| Trial dose | 2.5 mg/day | Oral | Dose studied in breast cancer trials. |
04 Effects
| Effect | Magnitude | Evidence | |
|---|---|---|---|
| Estradiol suppressionPotent selective aromatase inhibition lowers oestrogen. | Marked estradiol reduction | Clinical | |
| Reduced estrogenic side effectsLower estradiol reduces water retention and breast tissue stimulation in androgen users. | Less bloat / gyno risk | Observational |
05 Side effects
| Effect | Severity | Frequency | Evidence | Countermeasures |
|---|---|---|---|---|
| Estrogen deficiency symptomsHot flashes and joint pain typical of the AI class. | Moderate | Common | Clinical | |
| Adverse lipid / bone effectsLow oestrogen can worsen lipids and bone density over time. | Moderate | Uncommon | Observational |